Share-based Payment Arrangement, Expense of Regulus Therapeutics Inc. from 31 Dec 2010 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Regulus Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 31 Mar 2025.
  • Regulus Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $2,249,000, a 128% increase year-over-year.
  • Regulus Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $8,999,000, a 167% increase year-over-year.
  • Regulus Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $7,735,000, a 176% increase from 2023.
  • Regulus Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,801,000, a 29% increase from 2022.
  • Regulus Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,177,000, a 26% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Regulus Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $8,999,000 $2,249,000 +$1,264,000 +128% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $7,735,000 $2,463,000 +$1,427,000 +138% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $6,308,000 $2,422,000 +$1,449,000 +149% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $4,859,000 $1,865,000 +$1,483,000 +388% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $3,376,000 $985,000 +$575,000 +140% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $2,801,000 $1,036,000 +$640,000 +162% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $2,161,000 $973,000 +$613,000 +170% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $1,548,000 $382,000 -$39,000 -9.3% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,587,000 $410,000 -$590,000 -59% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $2,177,000 $396,000 -$275,000 -41% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $2,452,000 $360,000 -$447,000 -55% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $2,899,000 $421,000 -$333,000 -44% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $3,232,000 $1,000,000 +$309,000 +45% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $2,923,000 $671,000 +$201,000 +43% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $2,722,000 $807,000 +$115,000 +17% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $2,607,000 $754,000 +$125,000 +20% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $2,482,000 $691,000 -$132,000 -16% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q4 2020 $2,614,000 $470,000 -$4,000 -0.84% 01 Oct 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
Q3 2020 $2,618,000 $692,000 +$156,000 +29% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $2,462,000 $629,000 +$310,000 +97% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $2,152,000 $823,000 -$136,000 -14% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1
Q4 2019 $2,288,000 $474,000 -$1,582,000 -77% 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $3,870,000 $536,000 +$136,000 +34% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $3,734,000 $319,000 -$1,038,000 -76% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $4,772,000 $959,000 -$668,000 -41% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q4 2018 $5,440,000 $2,056,000 +$944,000 +85% 16 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $400,000 -$884,000 -69% 15 Oct 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $4,496,000 $1,390,000 +$106,000 +8.3% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $5,380,000 $1,357,000 -$1,508,000 -53% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $6,888,000 $1,627,000 -$754,000 -32% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $7,642,000 $1,112,000 -$2,306,000 -67% 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
Q3 2017 $9,948,000 $1,284,000 -$2,183,000 -63% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $12,131,000 $2,865,000 +$627,000 +28% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $11,504,000 $2,381,000 -$1,368,000 -36% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $12,872,000 $3,418,000 -$344,000 -9.1% 01 Oct 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
Q3 2016 $13,216,000 $3,467,000 +$833,000 +32% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $12,383,000 $2,238,000 -$3,631,000 -62% 01 Apr 2016 30 Jun 2016 10-Q 02 Aug 2017 2017 Q2
Q1 2016 $16,014,000 $3,749,000 +$646,000 +21% 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017 2017 Q1
Q4 2015 $15,368,000 $3,762,000 +$1,434,000 +62% 01 Oct 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
Q3 2015 $13,934,000 $2,634,000 +$1,007,000 +62% 01 Jul 2015 30 Sep 2015 10-Q 02 Nov 2016 2016 Q3
Q2 2015 $12,927,000 $5,869,000 +$4,185,000 +249% 01 Apr 2015 30 Jun 2015 10-Q 03 Aug 2016 2016 Q2
Q1 2015 $8,742,000 $3,103,000 +$1,703,000 +122% 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016 2016 Q1
Q4 2014 $7,039,000 $2,328,000 +$1,430,000 +159% 01 Oct 2014 31 Dec 2014 10-K 03 Mar 2017 2016 FY
Q3 2014 $5,609,000 $1,627,000 +$649,000 +66% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $4,960,000 $1,684,000 +$925,000 +122% 01 Apr 2014 30 Jun 2014 10-Q 05 Aug 2015 2015 Q2
Q1 2014 $4,035,000 $1,400,000 +$613,000 +78% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q1
Q4 2013 $3,422,000 $898,000 +$80,000 +9.8% 01 Oct 2013 31 Dec 2013 10-K 23 Feb 2016 2015 FY
Q3 2013 $3,342,000 $978,000 +$564,000 +136% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $2,778,000 $759,000 +$554,000 +270% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $2,224,000 $787,000 +$674,000 +596% 01 Jan 2013 31 Mar 2013 10-Q 09 May 2014 2014 Q1
Q4 2012 $1,550,000 $818,000 01 Oct 2012 31 Dec 2012 10-K 19 Feb 2015 2014 FY
Q3 2012 $414,000 +$218,000 +111% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q3
Q2 2012 $205,000 01 Apr 2012 30 Jun 2012 10-Q/A 16 Aug 2013 2013 Q2
Q1 2012 $113,000 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013 2013 Q1
Q3 2011 $196,000 01 Jul 2011 30 Sep 2011 10-Q 19 Nov 2012 2012 Q3

Regulus Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $7,735,000 +$4,934,000 +176% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $2,801,000 +$624,000 +29% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $2,177,000 -$746,000 -26% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $2,923,000 +$309,000 +12% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $2,614,000 +$326,000 +14% 01 Jan 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
2019 $2,288,000 -$3,152,000 -58% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
2018 $5,440,000 -$2,202,000 -29% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2017 $7,642,000 -$5,230,000 -41% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
2016 $12,872,000 -$2,496,000 -16% 01 Jan 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
2015 $15,368,000 +$8,329,000 +118% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
2014 $7,039,000 +$3,617,000 +106% 01 Jan 2014 31 Dec 2014 10-K 03 Mar 2017 2016 FY
2013 $3,422,000 +$1,872,000 +121% 01 Jan 2013 31 Dec 2013 10-K 23 Feb 2016 2015 FY
2012 $1,550,000 +$725,000 +88% 01 Jan 2012 31 Dec 2012 10-K 19 Feb 2015 2014 FY
2011 $825,000 +$222,000 +37% 01 Jan 2011 31 Dec 2011 10-K 28 Feb 2014 2013 FY
2010 $603,000 01 Jan 2010 31 Dec 2010 10-K 19 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.